ODACPhotoprotectionSkin Cancer

Controversies in Photoprotection

By June 1, 2020April 12th, 2023No Comments

Dermatology News

Video Pearls

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive OncodermatologyProgram in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York.

Learn More

Controversies in Photoprotection

featuring Dr. Adam Friedman

Journal of Drugs in Dermatology partners Next Steps in Derm and ODAC Dermatology Aesthetic and Surgical Conference interviewed Dr. Adam Friedman, Professor, Interim Chair of Dermatology, and Residency Program Director at George Washington University, on some of the common misconceptions and controversies surrounding photoprotection.

Debunking Misconceptions on Photoprotection

While ample evidence has shown that sunscreen not only reduces the incidences of melanoma, it also helps prevent  accelerated skin aging, many misconceptions about sunscreen are preventing patients from using what we have available to them.

Watch as Dr. Friedman debunks some of the current myths surrounding photoprotection and provides guidance on what we should really pay attention to.

Explore Photoprotection Articles

ODAC Orlando Dermatology, Aesthetic & Surgical Conference

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a distinguished ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century. Founded in 2003 by dermatology pioneer, Dr. Perry Robins, the ODAC Dermatology Conference provides nearly 700 dermatologists, residents, nurse practitioners and physician assistants with important annual updates and fresh practical pearls in the field of medical, cosmetic and surgical dermatology in a highly interactive format.

Reasons to Attend ODAC 2021

  • Discuss the next generation of diagnostic approaches and evidence-based dermatology treatments
  • Observe cutting-edge procedures and techniques with live demonstrations of novel products and emerging technologies
  • Review clinical trial results and discuss case-studies in both large and small group settings
  • Cultivate relationships with colleagues and leaders actively shaping the future of dermatology
  • Earn CME –  up to 31 AMA PRA Category 1 Credits™
Register for ODAC 2021 Now

You May Also Like

Journal of Drugs in Dermatology JDD Article about Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma

Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma

| Featured Articles, Latest News, Skin Cancer | No Comments
From the Vault: Noninvasive RNA from Tape Strips Differentiates AK from SCC In this article from the JDD vault, authors report a single center study that used adhesive tape strips…
Journal of Drugs in Dermatology JDD Article about ChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines?

ChatGPT and DeepSeek in Dermatologic Practice: Do Artificial Intelligence Models Adhere to Psoriasis Treatment Guidelines?

| Featured Articles, Latest News, Psoriasis, Social and Technology | No Comments
A comparative evaluation finds promising concordance but highlights gaps that require In the February JDD, authors compared two large language models, ChatGPT and DeepSeek, against the 2021 American Academy of…
Journal of Drugs in Dermatology JDD Article about Clinical Efficacy of Second-Generation Tetracyclines as First-Line Systemic Agents for Gingival Lichen Planus

Clinical Efficacy of Second-Generation Tetracyclines as First-Line Systemic Agents for Gingival Lichen Planus

| Featured Articles, Latest News, Medical Derm | No Comments
Retrospective JDD study finds minocycline or doxycycline (100 mg twice daily) led to meaningful improvement in inflammatory gingival OLP in two months In a recent JDD report of 254 biopsy‑confirmed…

Leave a Reply